<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318913</url>
  </required_header>
  <id_info>
    <org_study_id>53392216.0.0000.5699</org_study_id>
    <nct_id>NCT03318913</nct_id>
  </id_info>
  <brief_title>Vascular Function, Fish Protein Hydrolysates and Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effect of Acute Fish Protein Hydrolysates Ingestion on Vascular Function of the Type 2 Diabetes Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease of abnormal carbohydrate
      metabolism which is related with high morbidity and mortality rates caused by its
      complications. One of the major diabetes-related arterial phenotypes thought to be
      responsible for development of cardiovascular disease is endothelial dysfunction. Nitric
      oxide (NO) is a potent molecule derived of endothelium, which plays key role in control of
      vascular tone. In T2DM present endothelial dysfunction due to reduced NO bioavailability.
      Fish protein hydrolysates (FPH) have been showed to present antioxidant peptides (and high
      value of ACE inhibition activity. Therefore, the present study aimed to examine whether
      single dose of FPH ingestion would reversal macro- and microvascular endothelial dysfunction
      in T2DM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Actual">March 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated dilation</measure>
    <time_frame>60 min after nutritional intervention</time_frame>
    <description>macrovascular endothelial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Near infrared spectroscopy</measure>
    <time_frame>70 min after nutritional intervention</time_frame>
    <description>microvascular endothelial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High performance liquid chromatography</measure>
    <time_frame>75 min after nutritional intervention</time_frame>
    <description>serum amino acids</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Health control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Health young subjects free of diabetes mellitus and nutritional intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DM Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sucralose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DM FHP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fish protein hydrolysates</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5g of the sucralose administered as white plastic capsules</description>
    <arm_group_label>DM Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fish protein hydrolysates</intervention_name>
    <description>5g of the FPH dissolving in 100 mL of water</description>
    <arm_group_label>DM FHP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

        Exclusion Criteria:

          -  History of symptomatic coronary artery disease;

          -  Stroke or other known atherosclerotic disease;

          -  Cancer;

          -  HIV positive;

          -  Alcohol or drug abuse within the past 6 months previous the visit 1;

          -  use any antioxidant supplementation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Federal University of Rio de Janeiro</name>
      <address>
        <city>Maca√©</city>
        <state>Rio De Janeiro</state>
        <zip>27979000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Thiago Alvares</investigator_full_name>
    <investigator_title>D.sc</investigator_title>
  </responsible_party>
  <keyword>Vascular function</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Fish protein hydrolysates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

